CAM
BBOT

Cormorant Asset Management’s BridgeBio Oncology BBOT Stock Holding History

Cormorant Asset Management’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$136M Hold
17,878,594
– – 6.98% 2
2026
Q1 		$160M Hold
17,878,594
– – 8.04% 2
2025
Q4 		$224M Hold
17,878,594
– – 10.35% 2
2025
Q3 		$207M Buy
17,878,594
+14,969,594
+515% +$156M 14.29% 1
2025
Q2 		$30.9M Hold
2,909,000
– – 2.3% 13
2025
Q1 		$32.9M Hold
2,909,000
– – 2.47% 11
2024
Q4 		$30.5M Hold
2,909,000
– – 1.68% 16
2024
Q3 		$30.4M Hold
2,909,000
– – 1.61% 22
2024
Q2 		$29.7M Hold
2,909,000
– – 1.72% 17
2024
Q1 		$30.3M Buy
+2,909,000
New +$30.1M 1.33% 24

Other funds holding BBOT

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cormorant Asset Management's BBOT Position: Q2 2026 in Review

Cormorant Asset Management held its BridgeBio Oncology (BBOT) position steady in Q2 2026 at 17,878,594 shares worth $136M. The position accounts for 6.98% of the portfolio, ranked #2.

Cormorant Asset Management first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $224M in Q4 2025. 65 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Cormorant Asset Management held 17,878,594 shares of BridgeBio Oncology worth $136M as of Q2 2026.
  • Cormorant Asset Management left its BridgeBio Oncology share count unchanged in Q2 2026.
  • BridgeBio Oncology made up 6.98% of Cormorant Asset Management's portfolio in Q2 2026, its #2 holding.
  • Cormorant Asset Management first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
  • Cormorant Asset Management's BridgeBio Oncology position peaked at $224M in Q4 2025.
  • 65 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Cormorant Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.